ATXS - Astria Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$19.40
DETAILS
HIGH:
$26.00
LOW:
$13.00
MEDIAN:
$20.00
CONSENSUS:
$19.40
UPSIDE:
54.21%
About Astria Therapeutics, Inc. (https://www.astriatx.com)
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Jill C. Milne | Co-Founder, Chief Executive Officer, President & Director | 1968 | $967,338 USD |
| Christopher J. Morabito | Chief Medical Officer | 1970 | $690,824 USD |
| Benjamin S. Harshbarger | Chief Legal Officer | 1969 | $658,041 USD |
| Noah Clauser | Chief Financial Officer & Treasurer | 1973 | $621,406 USD |
| Andrea L. Matthews | Chief Business Officer | 1982 | – |
| Andrew A. Komjathy | Chief Commercial Officer | 1963 | – |
| John Ruesch | Senior Vice President of Pharmaceutical Sciences & Technical Operations | – | – |
| Keri McGrail | Chief Human Resources Officer | – | – |
| Rafif Dagher | Senior Vice President and Head of Discovery, Nonclinical Development & Translational Research | – | – |